Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ramucirumab Clear all
Terminated Phase 2 Interventional Results available

Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy

NCT03904108
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Ramucirumab
Drug
Lead sponsor
ROGER S KERESZTES MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Sep 17, 2026, 4:11 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

NCT02411448
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Cancer
Interventions
Ramucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Denver, Colorado • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 17, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

NCT02514551
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Ramucirumab, Paclitaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
Duarte, California • Westwood, Kansas • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 17, 2026, 4:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Ramucirumab (LY3009806) in Healthy Participants

NCT04495478
View directory record Official record
Conditions
Healthy
Interventions
Ramucirumab - IV, Placebo - IV, Ramucirumab - SC, Placebo - SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 17, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT03686488
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Gastric Cancer
Interventions
TAS 102, Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 17, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

NCT01017731
View directory record Official record
Conditions
Cancer, Solid Tumor
Interventions
IMC-1121B, Moxifloxacin, Diphenhydramine
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
7
States / cities
Atlanta, Georgia • Metairie, Louisiana • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Sep 17, 2026, 4:11 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

NCT04145700
View directory record Official record
Conditions
Synovial Sarcoma
Interventions
Ramucirumab, Gemcitabine, Docetaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Months to 29 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 17, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

NCT01515306
View directory record Official record
Conditions
Malignant Solid Tumor
Interventions
ramucirumab (IMC-1121B), paclitaxel
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
6
States / cities
Ann Arbor, Michigan • Detroit, Michigan • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Sep 17, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

NCT01246960
View directory record Official record
Conditions
Stomach Cancer, Esophageal Cancer
Interventions
Ramucirumab, Placebo, Oxaliplatin, Leucovorin, 5-Fluorouracil
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
58
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Alhambra, California + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Sep 17, 2026, 4:11 AM EDT
Completed Phase 1 Interventional Results available

A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)

NCT02079636
View directory record Official record
Conditions
Carcinoma, Non-small Cell Lung
Interventions
Abemaciclib, Pemetrexed, Gemcitabine, Ramucirumab, LY3023414, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Fayetteville, Arkansas • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Sep 17, 2026, 4:11 AM EDT
Withdrawn Phase 2 Interventional

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

NCT04179110
View directory record Official record
Conditions
Transitional Cell Carcinoma
Interventions
Pembrolizumab and Ramucirumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 17, 2026, 4:11 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

NCT03502746
View directory record Official record
Conditions
Mesothelioma, Malignant
Interventions
Nivolumab, Ramucirumab
Drug
Lead sponsor
Arkadiusz Z. Dudek, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Tampa, Florida • Baltimore, Maryland • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 17, 2026, 4:11 AM EDT
Recruiting Phase 2 Interventional

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

NCT06031688
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Ramucirumab, Tepotinib
Procedure · Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Minutes and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
266
States / cities
Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 222 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 17, 2026, 4:11 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

NCT04340882
View directory record Official record
Conditions
Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Docetaxel, Pembrolizumab, Ramucirumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 17, 2026, 4:11 AM EDT
Not listed Phase 1Phase 2 Interventional

Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma

NCT03995017
View directory record Official record
Conditions
Esophagus Cancer, Adenocarcinoma, Stomach Cancer, Adenocarcinoma
Interventions
Rucaparib, Ramucirumab, Nivolumab
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Chicago, Illinois • Fairway, Kansas • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Sep 17, 2026, 4:11 AM EDT
Withdrawn Phase 1Phase 2 Interventional

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT03739801
View directory record Official record
Conditions
Locally Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Liposomal Irinotecan, Quality-of-Life Assessment, Questionnaire Administration, Ramucirumab
Drug · Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 17, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma

NCT03141034
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma
Interventions
Irinotecan, Ramucirumab, Blood for angiome profiling, Blood for cfDNA
Drug · Genetic
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
Miami, Florida • Tampa, Florida • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 17, 2026, 4:11 AM EDT
Recruiting Phase 2 Interventional

A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

NCT07603856
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Metastatic Lung Cancer
Interventions
Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 17, 2026, 4:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca

NCT04921904
View directory record Official record
Conditions
Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
Interventions
Abemaciclib, Ramucirumab
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 17, 2026, 4:11 AM EDT
Completed Phase 1 Interventional

Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy

NCT00786383
View directory record Official record
Conditions
Cancer
Interventions
IMC-1121B, 1121B
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Indianapolis, Indiana • Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2013 · Synced Sep 17, 2026, 4:11 AM EDT
Recruiting Phase 2 Interventional

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

NCT07546812
View directory record Official record
Conditions
HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Interventions
Denikitug, Nivolumab, Ramucirumab, Paclitaxel
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Boston, Massachusetts • Albany, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 17, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

NCT03971474
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
889
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 593 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 17, 2026, 4:11 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer

NCT02314117
View directory record Official record
Conditions
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Ramucirumab, Capecitabine, Cisplatin, Placebo, Fluorouracil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
25
States / cities
Fayetteville, Arkansas • Bakersfield, California • Fullerton, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Sep 17, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

NCT01246986
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
LY2157299, Sorafenib, Ramucirumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
10
States / cities
Fayetteville, Arkansas • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 17, 2026, 4:11 AM EDT